real-world

Original Contribution

Auryon Laser in Peripheral Arterial Interventions: A Single-Center Experience (Auryon-SCE)

05/11/2022

Nicolas W. Shammas, MD¹; Gail A Shammas, RN¹; Grace Halupnik, MD¹; Nicholas Fedele, MD¹; Katie Comp, MD¹; Emma-Marie Taleb, MD¹;
Sue Jones-Miller, MD¹; Andrew N. Shammas, MD¹; Venkat Shankarraman, MD²

Nicolas W. Shammas, MD1; Gail A Shamm...

The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...

The Auryon 355-nm laser...

05/11/2022

Journal of Invasive Cardiology

How Clinical Pathways Are Growing

06/16/2020

In this new series, Journal of Clinical Pathways features insights from the editorial advisory board members pertaining to a specific question on pathways or value-based care.  For the first edition of Ask the...

In...

06/16/2020

Journal of Clinical Pathways

$Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States$

Research Reports

Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States

02/18/2020

Andrew J Klink, PhD, MPH

Chadi Nabhan, MD, MBA, FACP

Choo Hyung Lee, MS

JaLyna Laney, RN, OCN

Yin Yang, MS

Anna G Purdum, PharmD, MS

Bruce A Feinberg, DO

Abstract: Given new therapeutic advances that are potentially curative in diffuse large B-cell lymphoma (DLBCL), it is important to understand what has been observed to date in this population to assess improvement...

...

02/18/2020

Journal of Clinical Pathways